CARMEL, IN--(Marketwire - May 07, 2008) - Bonaventura Reproductive Medicine today announced it will offer the Repromedix’s PlanAhead test, an innovative blood test that provides an assessment of a woman’s egg supply by combining multiple factors including the measurement of ovary-related hormones AMH, Inhibin B, and FSH. The window of opportunity for a woman to have children by natural conception is dependent upon an adequate supply of eggs, which inevitably declines as a woman ages and her “biological clock ticks.” PlanAhead enables a woman to compare her estimated egg supply with the normal range expected for women of the same age.
